Over-expression of facilitative glucose transporter genes in human cancer

Yamamoto, T.; Seino, Yutaka; Fukumoto, Hirofumi; Koh, Gyohan; Yano, Hideki; Inagaki, Nobuya; Yamada, Yoshio; Inoue, Kazutomo; Manabe, Tadao; Imura, Hiroo

doi:10.1016/0006-291x(90)91263-r

Cited by 423 publications

(282 citation statements)

References 7 publications

Supporting

Mentioning

261

Contrasting

Unclassified

Order By: Relevance

“…It is also documented that the colonic carcinoma cell line, Caco-2, has a high rate of glucose utilisation and glycogen content (Chantret et al, 1994). Many tumours, including colonic carcinomas, have been found to express the high affinity glucose transporter, GLUT1 (Yamamoto et al, 1990). Here, we show that 83.3% of carcinomas displaying significantly reduced levels of MCT1 express GLUT1.…”

Section: Molecular and Cellular Pathologymentioning

confidence: 52%

“…It has been reported, however, that colorectal cancers, in common with many other malignancies, have enhanced glucose utilisation and glycolytic metabolism (Eigenbrodt et al, 1985;Holm et al, 1995). In many cases this increase in glucose utilisation is often accompanied by expression of the high affinity glucose transporter, GLUT1 (Yamamoto et al, 1990). GLUT 1 expression is normally confined to erythrocytes and cells at the blood -brain interface, but is expressed by cells transformed with ras or src oncogenes in culture (Flier et al, 1987) and by a number of malignant cell types (Brown and Wahl, 1993;Nagase et al 1995;Mellanen et al, 1994).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Molecular changes in the expression of human colonic nutrient transporters during the transition from normality to malignancy

et al. 2002

View full text Add to dashboard Cite

Healthy colonocytes derive 60 -70% of their energy supply from short-chain fatty acids, particularly butyrate. Butyrate has profound effects on differentiation, proliferation and apoptosis of colonic epithelial cells by regulating expression of various genes associated with these processes. We have previously shown that butyrate is transported across the luminal membrane of the colonic epithelium via a monocarboxylate transporter, MCT1. In this paper, using immunohistochemistry and in situ hybridisation histochemistry, we have determined the profile of MCT1 protein and mRNA expression along the crypt to surface axis of healthy human colonic tissue. There is a gradient of MCT1 protein expression in the apical membrane of the cells along the crypt-surface axis rising to a peak in the surface epithelial cells. MCT1 mRNA is expressed along the cryptsurface axis and is most abundant in cells lining the crypt. Analysis of healthy colonic tissues and carcinomas using immunohistochemistry and Western blotting revealed a significant decline in the expression of MCT1 protein during transition from normality to malignancy. This was reflected in a corresponding reduction in MCT1 mRNA expression, as measured by Northern analysis. Carcinoma samples displaying reduced levels of MCT1 were found to express the high affinity glucose transporter, GLUT1, suggesting that there is a switch from butyrate to glucose as an energy source in colonic epithelia during transition to malignancy. The expression levels of MCT1 in association with GLUT1 could potentially be used as determinants of the malignant state of colonic tissue.

show abstract

Section: Molecular and Cellular Pathologymentioning

confidence: 52%

mentioning

confidence: 99%

Molecular changes in the expression of human colonic nutrient transporters during the transition from normality to malignancy

et al. 2002

View full text Add to dashboard Cite

show abstract

“…In addition, an increased concentration of the mRNA has been linked to the increase in the number of glucose transporters in the malignant cell. In man, overexpression of GLUT1 and GLUT3 has been observed in several tumour types, including cerebral tumours, hepatocellular carcinoma and pancreatic tumours [25][26][27][28]. Furthermore, an increase in the activity of several enzymes controlling the glycolytic pathway has been demonstrated (hexokinase, phosphofructokinase, pyruvate dehydrogenase) [29].…”

Section: Biological Characteristics Of 18-fdgmentioning

confidence: 99%

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

Rigo¹,

Paulus²,

et al. 1996

View full text Add to dashboard Cite

Abstract. Positron emission tomography (PET) is now primarily used in oncological indication owing to the successful application of fluorine-18 fluorodeoxyglucose (FDG) in an increasing number of clinical indications at different stages of diagnosis, and for staging and followup. This review first considers the biological characteristics of FDG and then discusses methodological considerations regarding its use. Clinical indications are considered, and the results achieved in respect of various organs and tumour types are reviewed in depth. The review concludes with a brief consideration of the ways in which clinical PET might be improved.

show abstract

“…The high metabolism and increased rates of glucose consumption of cancer cells are associated with changes in the levels and isoenzyme compositions of glycolytic enzymes (Golshani, 1992) and the overexpression of Gluts (Brown and Wahl, 1993;Merrall et al, 1993;Yamamoto et al, 1990) compared with the surrounding normal tissues. Changes in the rate of glucose uptake and overexpression of glucose transporters are also associated with adaption to hypoxia partly due to increased dependency on glycolysis as an energy source (Ismail-Beigi, 1993;Merrall et al, 1993), a condition that may arise in rapidly growing tumors (Vaupel et al, 1989).…”

Section: Effects Of Aimp2-dx2 On Glucose Uptake and Transportersmentioning

confidence: 99%

Lentiviral Vector-Mediated shRNA against AIMP2-DX2 Suppresses Lung Cancer Cell Growth through Blocking Glucose Uptake

Chang

Chung

Hwang

et al. 2012

Molecules and Cells

View full text Add to dashboard Cite

Aminoacyl-tRNA synthetases [ARS]-interacting multifunctional protein 2 (AIMP2) has been implicated in the control of cell fate and lung cell differentiation. A variant of AIMP2 lacking exon 2 (AIMP2-DX2) is expressed in different cancer cells. We previously studied the expression level of AIMP2-DX2 in several lung cell lines and reported elevated expression levels of AIMP2-DX2 in NCI-H460 and NCI-H520. Here, we report that the suppression of AIMP2-DX2 by lentivirus mediated short hairpin (sh)RNA (sh-DX2) decreased the rate of glucose uptake and glucose transporters (Gluts) in NCI-H460 cells. Down-regulation of AIMP2-DX2 reduced glycosyltransferase (GnT)-V in the Golgi apparatus, while inducing the GnT-V antagonist GnT-III. Down-regulation of AIMP2-DX2 also suppressed the epidermal growth factor receptor/mitogen activated protein kinase (EGFR/MAPK) signaling pathway, leading to the decrease of the proliferation marker Ki-67 expression in nuclei. Furthermore, dual luciferase activity reduced capdependent protein translation in cells infected with sh-DX2. These results suggest that AIMP2-DX2 may be a relevant therapeutic target for lung cancer, and that the sh-DX2 lentiviral system can be an appropriate method for lung cancer therapy.

show abstract

Over-expression of facilitative glucose transporter genes in human cancer

Cited by 423 publications

References 7 publications

Molecular changes in the expression of human colonic nutrient transporters during the transition from normality to malignancy

Molecular changes in the expression of human colonic nutrient transporters during the transition from normality to malignancy

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

Lentiviral Vector-Mediated shRNA against AIMP2-DX2 Suppresses Lung Cancer Cell Growth through Blocking Glucose Uptake

Contact Info

Product

Resources

About